Cagrilintide 10mg (10 vials/Kit): Long-Acting Amylin & Calcitonin Receptor Agonist for Metabolic Research

Cagrilintide is a novel, long-acting acylated synthetic analog of human amylin (islet amyloid polypeptide, $\text{IAPP}$). Engineered with targeted amino acid modifications and a lipophilic fatty acid moiety, Cagrilintide acts as a non-selective, high-affinity dual agonist at amylin receptors ($\text{AMY}_1$, $\text{AMY}_2$, and $\text{AMY}_3$) as well as calcitonin receptors ($\text{CTR}$). In neuroendocrine and metabolic research models, activation of central amylin pathways in the area postrema and nucleus of the solitary tract ($\text{NST}$) suppresses appetite signals, delays gastric emptying, and modulates postprandial glucagon secretion. Sourcing Cagrilintide 10mg (10 vials/Kit) provides metabolic researchers, endocrinological facilities, and obesity research laboratories with an advanced analytical reagent engineered to evaluate satiety signaling, energy expenditure homeostasis, and synergistic dual-pathway metabolic co-formulations.

Native human amylin exhibits a short elimination half-life ($\sim13\text{ minutes}$) and a high propensity for irreversible amyloid fibril aggregation, limiting its utility in longitudinal cell culture and animal bioassays. Cagrilintide overcomes these structural limitations through strategic sequence substitutions and $C$-terminal acylation with a diacid fatty chain. This structural lipid modification facilitates reversible binding to circulating serum albumin, protecting the peptide backbone against enzymatic cleavage by neutral endopeptidases ($\text{NEP}$) and extending its functional half-life to enable sustained receptor activation:

In preclinical metabolic co-culture and energetic models, Cagrilintide exhibits distinct, complementary mechanisms when investigated alongside glucagon-like peptide-1 receptor ($\text{GLP-1R}$) agonists. While $\text{GLP-1R}$ activation primarily targets hypothalamic arcuate nucleus signaling to regulate insulin release and energy intake, Cagrilintide engages hindbrain amylin circuits to enhance satiation and reduce meal size. Combining these distinct pathways generates potent synergistic effects on body weight regulation and glycemic control without compounding off-target gastrointestinal toxicity.

The Cagrilintide 10mg (10 vials/Kit) packaging supplies a total yield of 100mg active research peptide material (10mg per vial) distributed across ten individual USP Type I borosilicate glass vials. Freeze-dried under sterile vacuum conditions into a stable, white lyophilized cake, this multi-vial format allows laboratory personnel to reconstitute only the working volume needed for active assay cycles, keeping remaining stock preserved in deep-freeze stasis to protect against thermal degradation and hydrolytic cleavage.

Dual Amylin/Calcitonin Receptor Agonism, Satiety Kinetics, and Technical Specifications

The primary scientific value of Cagrilintide 10mg (10 vials/Kit) stems from its dual receptor binding affinity, prolonged pharmacokinetic profile, and targeted neuroendocrine pathways:

• Dual AMYR & CTR Receptor Agonism: Binds with high affinity to amylin receptor subtypes ($\text{AMY}_1$, $\text{AMY}_2$, $\text{AMY}_3$) and calcitonin receptors ($\text{CTR}$), driving central satiation signals in hindbrain neural networks.

• Albumin-Binding Acylation: Integrated fatty diacid side-chain facilitates reversible serum albumin binding, significantly extending biological half-life and circulating bioactivity.

• Inhibition of Amyloid Fibrillization: Sequence modifications prevent self-aggregation and toxic $\beta$-sheet amyloid plaque formation common to native human amylin ($\text{IAPP}$).

• Gastric Emptying & Postprandial Glucagon Modulation: Delays gastric motility and suppresses postprandial glucagon hypersecretion in pancreatic alpha-cell culture models.

• Synergistic Metabolic Co-Formulation Potential: Demonstrates complementary biological cross-talk when combined with $\text{GLP-1R}$ and $\text{GIP}$ agonists for advanced obesity and metabolic research.

• Ultra-High Chemical Purity ($\ge$99.0%): Manufactured via automated Solid-Phase Peptide Synthesis ($\text{SPPS}$) and purified using preparative High-Performance Liquid Chromatography ($\text{HPLC}$) to ensure complete removal of deletion sequences and synthesis byproducts.

Reconstitution Guidelines, Laboratory Storage Standards, and Quality Protocols

Achieving reproducible, publication-grade results when working with Cagrilintide 10mg (10 vials/Kit) requires strict adherence to standardized aseptic reconstitution and climate-controlled storage protocols.

Perform all reconstitution procedures inside a certified Class II Biosafety Cabinet:

1. Temperature Balancing: Allow the frozen Cagrilintide vial to adjust to ambient room temperature prior to solvent introduction to eliminate moisture condensation inside the glass container.

2. Septum Sanitization: Remove the protective plastic flip-cap and thoroughly wipe the synthetic rubber stopper with a fresh 70% isopropyl alcohol pad. Allow the surface to dry completely.

3. Slow Diluent Addition: Using a sterile syringe equipped with a fine-gauge needle, draw the required volume of Bacteriostatic Water (0.9% benzyl alcohol), Sterile Normal Saline (0.9% NaCl), or Phosphate-Buffered Saline (PBS). Direct the liquid stream against the inner glass wall so it trickles slowly over the lyophilized cake.

4. Gentle Hydration: Allow the diluent to fully hydrate the powder cake for 2 minutes. Gently roll the vial between your palms or swirl in smooth circular motions until clear. Never vortex or shake violently, as high-shear agitation can disrupt peptide tertiary structures and induce protein foaming.

5. Micro-Aliquot Strategy: For multi-week testing protocols, divide reconstituted liquid into sterile, single-use microcentrifuge tubes under aseptic conditions to prevent atmospheric oxidation and eliminate repeated freeze-thaw cycles.

Batch Quality Documentation & Traceability: Every production lot of Cagrilintide 10mg (10 vials/Kit) undergoes third-party analytical testing. High-Performance Liquid Chromatography (HPLC) chromatograms confirm component purity exceeding 99.0%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms precise theoretical molecular mass. Each shipment includes a batch-specific Certificate of Analysis (COA) documenting chemical purity, residual solvent analysis, heavy metal screens, and bacterial endotoxin levels (<0.05 EU/mg) to satisfy institutional compliance requirements.

Strict Regulatory & Research Compliance Statement: Cagrilintide 10mg (10 vials/Kit) is produced, packaged, and distributed exclusively for in vitro laboratory research, academic experimentation, chemical synthesis, and preclinical research. Cagrilintide 10mg (10 vials/Kit) is strictly not intended, formulated, or approved for human or animal consumption, therapeutic medical treatment, clinical diagnostic work, or cosmetic applications. All handling must be conducted by certified research personnel operating within equipped laboratory facilities in compliance with OSHA workplace safety regulations and institutional biosafety protocols.